Trials / Completed
CompletedNCT01904279
A Study of Subcutaneously (SC) Administered Tocilizumab (TCZ) in Participants With Polyarticular-Course Juvenile Idiopathic Arthritis (pJIA)
A Phase Ib, Open-Label, Multicenter Study to Investigate the Pharmacokinetics, Pharmacodynamics, and Safety of Tocilizumab Following Subcutaneous Administration to Patients With Polyarticular Juvenile Idiopathic Arthritis
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 52 (actual)
- Sponsor
- Hoffmann-La Roche · Industry
- Sex
- All
- Age
- 1 Year – 17 Years
- Healthy volunteers
- Not accepted
Summary
This open-label, multicenter study evaluated the pharmacokinetics, pharmacodynamics and safety of SC administered TCZ in participants with pJIA.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Tocilizumab | Participants will receive 162 mg of TCZ as SC injection Q3W or Q2W for 52 weeks |
Timeline
- Start date
- 2013-07-01
- Primary completion
- 2016-05-01
- Completion
- 2016-05-01
- First posted
- 2013-07-22
- Last updated
- 2017-06-14
- Results posted
- 2017-03-16
Locations
35 sites across 12 countries: United States, Argentina, Australia, Brazil, Canada, France, Germany, Italy, Mexico, Russia, Spain, United Kingdom
Source: ClinicalTrials.gov record NCT01904279. Inclusion in this directory is not an endorsement.